文献速递核素与放射性配体治疗肿瘤 PET/CT

基于[68Ga]Ga-PSMA-11 PET的预后模型在[18F]F-flotufolastat显像下对[177Lu]Lu-PSMA I&T治疗结局的外部验证

Outcome Prediction After [177Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [68Ga]Ga-PSMA-11 PET-Based Model with [18F]F-Flotufolastat.
PubMed 文献 · J Nucl Med · 2026-10-01

该回顾性研究纳入174例接受[177Lu]Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者,在治疗前使用[18F]F-flotufolastat PET显像,外部验证基于[68Ga]Ga-PSMA-11 PET的预后模型。结果显示总生存预测C-index为0.71,PSA无进展生存预测C-index为0.62,PSA反应预测AUC为0.71,低风险组总生存和PSA无进展生存均显著优于高风险组。结论认为该模型在换用[18F]F-flotufolastat显像的独立人群中预测准确性相似。

要点

  • 总生存预测C-index为0.71(95% CI 0.67-0.76),与验证队列的0.72相近。
  • PSA无进展生存预测C-index为0.62(95% CI 0.57-0.67),低于验证队列的0.71。
  • 低风险组总生存21.8 vs 11.6个月(P<0.0001),PSA无进展生存6.9 vs 2.9个月(P=0.003)。

核心结论

  • 基于[68Ga]Ga-PSMA-11 PET的预后模型在换用[18F]F-flotufolastat显像的独立人群中,对总生存、PSA无进展生存和PSA反应的预测准确性相似。

研究设计与样本

  • 回顾性分析纳入单中心174例连续接受[177Lu]Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者。
  • 应用原预后模型中的Cox比例风险模型(总生存和PSA无进展生存)及逻辑回归模型(PSA反应)进行外部验证。
  • 模型性能采用Harrell一致性指数(C-index)和校准图评估,并按已发表截断值分层为低风险和高风险组。

主要发现

  • 估计总生存概率12个月为60%(95% CI 53%-68%),18个月为40%(95% CI 33%-49%)。
  • 总生存预测C-index为0.71(95% CI 0.67-0.76),验证队列为0.72(95% CI 0.68-0.76)。
  • PSA无进展生存估计概率3个月为56%(95% CI 49%-65%),6个月为34%(95% CI 27%-42%)。
  • PSA无进展生存预测C-index为0.62(95% CI 0.57-0.67),验证队列为0.71(95% CI 0.68-0.74)。
  • PSA反应预测AUC为0.71(95% CI 0.63-0.79),验证数据为0.78(95% CI 0.68-0.88)。

关键数值与推荐

  • 低风险组总生存显著长于高风险组(21.8 vs 11.6个月,P<0.0001)。
  • 低风险组PSA无进展生存显著长于高风险组(6.9 vs 2.9个月,P=0.003)。

临床怎么用

  • 该模型可在使用[18F]F-flotufolastat PET显像替代[68Ga]Ga-PSMA-11时辅助预测[177Lu]Lu-PSMA I&T治疗后的总生存和PSA反应。
  • 按模型截断值分层可识别总生存和PSA无进展生存获益更大的低风险患者。

局限性

  • 本研究为单中心回顾性分析。
  • PSA无进展生存预测的C-index(0.62)低于原验证数据(0.71),判别能力稍弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is an established treatment for metastatic castration-resistant prostate cancer, though responses vary. A prognostic model using [68Ga]Ga-PSMA-11 PET-derived parameters was developed to predict therapy outcomes. This retrospective analysis validates the model in an independent cohort imaged with [18F]F-flotufolastat ([18F]rhPSMA-7.3 PET) before [177Lu]Lu-PSMA I&T. Methods: In total, 174 consecutive patients treated with [177Lu]Lu-PSMA I&T at a single center were included in this analysis. The Cox proportional hazards models for overall survival (OS) and prostate-specific antigen (PSA) progression-free survival (PFS) and the logistic regression model for PSA response, as proposed in the prognostic model, were applied to our validation data. Model performance was evaluated using the Harrell concordance index (C-index) and calibration plots. OS, PSA-PFS, and PSA response were reported with median values and 95% CI, as well as stratified by published cutoff values into low- and high-risk groups. Results: The estimated OS probabilities were 60% (95% CI, 53%-68%) at 12 mo and 40% (95% CI, 33%-49%) at 18 mo. Our validation yielded a C-index of 0.71 (95% CI, 0.67-0.76) for OS prediction compared with a C-index of 0.72 (95% CI, 0.68-0.76) in the validation cohort. For PSA-PFS, the estimated probabilities were 56% (95% CI, 49%-65%) at 3 mo and 34% (95% CI, 27%-42%) at 6 mo, with a C-index of 0.62 (95% CI, 0.57-0.67) compared with a C-index of 0.71 (95% CI, 0.68-0.74) in the validation data. Low-risk patients had significantly longer OS (21.8 vs. 11.6 mo, P < 0.0001) and PSA-PFS (6.9 vs. 2.9 mo, P = 0.003) than did high-risk patients. The prognostic PSA response model showed slightly worse discrimination in our cohort (area under the receiver operating characteristic curve, 0.71; 95% CI, 0.63-0.79) than with the validation data (area under the receiver operating characteristic curve; 95% CI, 0.78, 0.68-0.88). Conclusion: Our results indicate accuracy similar to that of the prognostic model for prediction of OS and PSA-PFS and for PSA response in an independent patient population undergoing [177Lu]Lu-PSMA I&T radiopharmaceutical therapy with [18F]F-flotufolastat instead of [68Ga]Ga-PSMA-11.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Karimzadeh A, Fütterer C, Hansen K, et al. Outcome Prediction After [177Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [68Ga]Ga-PSMA-11 PET-Based Model with [18F]F-Flotufolastat. J Nucl Med. 2026. PMID: 42492997. doi:10.2967/jnumed.125.270944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。